GSK PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,673 GBX | +0.18% |
|
+1.33% | +15.36% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.7
GBP
Average target price
20.06
GBP
Spread / Average Target
+20.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.36% | 85.64B | |
| +33.67% | 664B | |
| +29.29% | 567B | |
| -7.08% | 354B | |
| +19.31% | 330B | |
| +4.74% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.58% | 148B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial
